Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01126671
Other study ID # 08-06-0271
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2008
Est. completion date June 2011

Study information

Verified date May 2018
Source Boston Children’s Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This double blind, randomized controlled trial compares two supplemental doses of vitamin D in health adolescents.


Description:

Vitamin D deficiency is a common problem. Currently, data do not support a recommended vitamin D supplementation dose for health adolescents to maintain normal vitamin D levels. This double blind, randomized controlled 12 week trial compares the use of two supplemental doses of vitamin D in this population.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date June 2011
Est. primary completion date June 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 11 Years to 18 Years
Eligibility Inclusion Criteria:

- 11-18 years old

- healthy

Exclusion Criteria:

- chronic disease

- use of medication known to effect bone or vitamin D metabolism

- abnormal vitamin D or calcium at screening

- pregnant

- body mass index <5% or >95%

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Supplemental Vitamin D
Subjects were randomized to either take 200 IU of vitamin D or 1000 IU of vitamin D daily for 11 weeks and labs were compared before and after.

Locations

Country Name City State
United States Children's Hospital Boston Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Boston Children’s Hospital

Country where clinical trial is conducted

United States, 

References & Publications (1)

Putman MS, Pitts SA, Milliren CE, Feldman HA, Reinold K, Gordon CM. A randomized clinical trial of vitamin D supplementation in healthy adolescents. J Adolesc Health. 2013 May;52(5):592-8. doi: 10.1016/j.jadohealth.2012.10.270. Epub 2012 Dec 23. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Baseline 25 Hydroxy Vitamin D (25OHD) Levels 25OHD will be drawn at baseline prior to starting vitamin D supplementation. Baseline
Primary Follow-up 25OHD Levels After 11weeks of treatment, repeat 25OHD levels will be drawn to assess subject response to vitamin D supplementation. 12 weeks
Secondary Baseline Assessment of Bone Markers Bone specific alkaline phosphatase, CTx, and osteocalcin will be assessed at baseline prior to subjects starting vitamin D supplementation Baseline
Secondary Assessment of Bone Markers at Follow-up After 11 weeks of vitamin D supplementation bone specific alkaline phosphatase, osteocalcin, and CTx will be repeated to see response to therapy. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06098846 - Human Transdermal Vitamin D Supplement Study N/A
Not yet recruiting NCT05616117 - Next-generation Effects of Vitamin D Supplementation in Pregnancy
Recruiting NCT04025489 - Vitamin D Supplementation on Surrogate Markers of Ageing, Ageing Genes, Glycemic and Metabolic Markers in North India N/A
Completed NCT04121533 - Vitamin D Supplementation in Knee Osteoarthritis N/A
Completed NCT03437421 - Myocardial Function and Vitamin D Supplementation in Diabetes. N/A
Not yet recruiting NCT02002000 - Chronic Pain and Vitamin D N/A
Completed NCT05867784 - Effect of Vitamin D Supplementation on the Efficacy of Ustekinumab in the Treatment of Crohn's Disease